Intellia Therapeutics (NTLA) Operating Income (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Operating Income data on file, last reported at -$100.5 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$100.5 million, up 16.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$420.7 million (up 22.24% YoY), and the FY2025 annual result was -$441.0 million, up 17.46% from the prior year.
• Operating Income fell to -$100.5 million in Q1 2026 per NTLA's latest filing, from -$98.7 million in the prior quarter.
• Over five years, Operating Income peaked at -$98.3 million in Q2 2022 and troughed at -$144.8 million in Q3 2024.
• A 5-year average of -$120.5 million and a median of -$114.0 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2025: Operating Income plunged 210.71% in 2022, then advanced 27.66% in 2025.
• A 5-year view of Operating Income shows it stood at -$110.1 million in 2022, then declined by 27.07% to -$139.9 million in 2023, then grew by 2.46% to -$136.4 million in 2024, then grew by 27.66% to -$98.7 million in 2025, then retreated by 1.85% to -$100.5 million in 2026.
• Business Quant data shows NTLA's Operating Income at -$100.5 million in Q1 2026, -$98.7 million in Q4 2025, and -$111.5 million in Q3 2025.